Alkermes plc (NASDAQ:ALKS) Holdings Raised by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in Alkermes plc (NASDAQ:ALKS) by 18.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,282 shares of the company’s stock after purchasing an additional 21,221 shares during the quarter. Victory Capital Management Inc. owned approximately 0.08% of Alkermes worth $3,815,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ALKS. EFG Asset Management North America Corp. lifted its stake in Alkermes by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 75,864 shares of the company’s stock valued at $1,828,000 after buying an additional 359 shares during the last quarter. United Services Automobile Association boosted its stake in Alkermes by 3.1% during the 2nd quarter. United Services Automobile Association now owns 13,208 shares of the company’s stock valued at $318,000 after purchasing an additional 400 shares during the period. Signaturefd LLC grew its position in Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after purchasing an additional 480 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Alkermes by 0.3% in the third quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock valued at $6,175,000 after purchasing an additional 700 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Alkermes by 44.4% during the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after buying an additional 703 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Stock Up 3.9 %

ALKS opened at $28.78 on Friday. Alkermes plc has a fifty-two week low of $22.22 and a fifty-two week high of $32.88. The company has a market capitalization of $4.66 billion, a P/E ratio of 14.25, a P/E/G ratio of 0.91 and a beta of 0.47. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The firm’s fifty day moving average price is $27.86 and its two-hundred day moving average price is $26.32.

Insiders Place Their Bets

In other Alkermes news, EVP Craig C. Hopkinson sold 58,996 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.08, for a total value of $1,774,599.68. Following the transaction, the executive vice president now directly owns 83,300 shares in the company, valued at approximately $2,505,664. This trade represents a 41.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.89% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Mizuho increased their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research report on Friday, October 25th. StockNews.com raised shares of Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. cut their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and a consensus target price of $35.42.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.